FOCUS-Express Scripts targets Amgen, Lilly migraine drugs in pricing shift
April 24, 2018 at 13:19 PM EDT
LOS ANGELES, April 24 (Reuters) - The largest U.S. manager of prescription benefits is telling drugmakers that the current pricing model is broken, and taking aim at Amgen Inc, Eli Lilly and Co and other makers of new migraine medicines to try and fix it.
